By Ruixue Ran, Xiaoliang Chen and Justin Wang ( October 21, 2022, 2:05 PM EDT) -- The China National Intellectual Property Administration recently made two benchmark administrative rulings in a major patent infringement dispute. The case was brought by international innovator drug company Boehringer Ingelheim Pharma GmbH & Co. KG against two Chinese generic drug makers Guangdong HEC Pharmaceutical Co. Ltd. and Yichang HEC Changjiang Pharmaceutical Co. Ltd., and a series of injunctions were granted against the two generic drug makers.[1] ...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.